Choose Category
COVID-19
CA Bridge: MOUD and COVID-19 National Emergency Response
March 16, 2020Guidance on how medications for opioid use disorder (MOUD) services must take immediate action to care for OUD patients while also slowing COVID-19 spread by implementing social distancing into all aspects of care.
COVID-19
SAMHSA: COVID-19 Guidance for Opioid Treatment Programs
March 16, 2020The Substance Abuse and Mental Health Services Administration (SAMHSA) provides guidance on pharmacotherapy for opioid use disorder availability in circumstances in which patients may be exposed to highly contagious infectious agents (such as COVID-19).
COVID-19
DEA: Narcotic Treatment Programs Exception to 21 CFR 1301.74(i)
March 16, 2020The Drug Enforcement Administration (DEA) has granted narcotic treatment programs (NTPs) an exception to 21 CFR 1301.74(i) in order to provide consistent dosing to patients enrolled.
COVID-19
NIDA: Potential Implications for Individuals with Substance Use Disorders
March 12, 2020Nora Volkow, M.D., Director of the National Institute on Drug Abuse (NIDA), highlights the added risks that populations with substance use disorder face during the COVID-19 pandemic.
Program Advisory Meeting
Delivery System and Payment Models
July 10, 2019Expert advisory meeting convened by FORE to consider the healthcare delivery system and payment model changes that are needed to facilitate access to treatment.
Program Advisory Meeting
Medical Education and Training
June 26, 2019Expert advisory meeting convened by FORE to explore opportunities in medical education and training related to preventing, screening, and treating opioid use disorder.